Aortic valve bioprosthesis SAPIEN 3

bovine tissuesutureless

Building on the benefits of the SAPIEN 3 platform SAPIEN 3 Ultra valve, powered by RESILIA tissue Advanced calcium-blocking technology*1 same tissue technology Same tissue technology used in the #1 implanted surgical valve in the US potential improvement Potential to improve valve longevity and reduce reintervention*†1 dry tissue storage The only transcatheter heart valve (THV) with dry tissue storage The SAPIEN 3 platform addresses the vital considerations for lifetime management Building on the benefits of the SAPIEN 3 platform Excellent outcomes in low-risk patients*2 1% death and disabling stroke at one year2 90.9% none/trace PVL at discharge3 6.5% new pacemaker rate at 30 days2 Facilitates future treatment options 100% successful post-TAVR coronary access rate (68/68 patients)4 The only valve with a THV-in-THV indication durability Durability that stands up to SAVR in low-risk patients.5 SAPIEN 3 valve durability proven similar to SAVR at 5 years5 *The PARTNER 3 Trial, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint of all-cause death, all stroke, and rehospitalization (valve-related or procedure-related and including heart failure) at one year, and multiple pre-specified secondary endpoints in low risk patients. PARTNER 3 Trial 5-Year Results in Low-Risk Patients - Low rates of cardiovascular mortality through five years (5.5% SAPIEN 3 TAVR to 5.1% SAVR). Low rates of all-cause mortality through five years (10.0% SAPIEN 3 TAVR vs. 8.2% with SAVR). Low rates of disabling stroke through five years (2.9% SAPIEN 3 TAVR to 2.7% SAVR).